MX2009004290A - Cathepsin proteases inhibitors. - Google Patents
Cathepsin proteases inhibitors.Info
- Publication number
- MX2009004290A MX2009004290A MX2009004290A MX2009004290A MX2009004290A MX 2009004290 A MX2009004290 A MX 2009004290A MX 2009004290 A MX2009004290 A MX 2009004290A MX 2009004290 A MX2009004290 A MX 2009004290A MX 2009004290 A MX2009004290 A MX 2009004290A
- Authority
- MX
- Mexico
- Prior art keywords
- optionally substituted
- alkynyl
- alkenyl
- proteases inhibitors
- cathepsin proteases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The invention provides compounds (I) and pharmaceutical compositions thereof, and more particularly, bicyclic carbamates, which are useful as cathepsin inhibitors, and methods for using such compounds or pharmaceutically acceptable salts thereof, wherein X is 0 or S; R1 is OR2, halo, (CR2)nR3, nitro, cyano, amino, aniido, sulfonamide, or an optionally substituted C1-6 alkyl, C2-6 alkenyl, or C3-6 alkynyl;R2 is H, (CR2)nR3, or an optionally substituted C1-6alkyl, C2-6 alkenyl or C3-6 alkynyl; R3 is an optionally substituted aryl, heteroaryl, carbocyciic ring or heterocyclic ring; m is 1-3; and n is 0-4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86250006P | 2006-10-23 | 2006-10-23 | |
| PCT/US2007/081635 WO2008051763A1 (en) | 2006-10-23 | 2007-10-17 | Cathepsin proteases inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009004290A true MX2009004290A (en) | 2009-07-27 |
Family
ID=39091868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009004290A MX2009004290A (en) | 2006-10-23 | 2007-10-17 | Cathepsin proteases inhibitors. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2078027A1 (en) |
| JP (1) | JP2010507681A (en) |
| KR (1) | KR20090064463A (en) |
| CN (1) | CN101589047A (en) |
| AU (1) | AU2007309195A1 (en) |
| BR (1) | BRPI0717348A2 (en) |
| CA (1) | CA2667816A1 (en) |
| MX (1) | MX2009004290A (en) |
| WO (1) | WO2008051763A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2370451B1 (en) | 2008-12-02 | 2016-11-16 | Wave Life Sciences Japan, Inc. | Method for the synthesis of phosphorus atom modified nucleic acids |
| KR101885383B1 (en) | 2009-07-06 | 2018-08-03 | 웨이브 라이프 사이언시스 리미티드 | Novel nucleic acid prodrugs and methods of use thereof |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| AU2012284265B2 (en) | 2011-07-19 | 2017-08-17 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| SG11201500232UA (en) | 2012-07-13 | 2015-04-29 | Wave Life Sciences Pte Ltd | Chiral control |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| US10149905B2 (en) | 2014-01-15 | 2018-12-11 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| WO2015108047A1 (en) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| SG10201912897UA (en) | 2014-01-16 | 2020-02-27 | Wave Life Sciences Ltd | Chiral design |
| WO2016014522A1 (en) | 2014-07-21 | 2016-01-28 | Brandeis University | Inhibitors of deubiquitinating proteases |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2812635B1 (en) * | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION AND USE AS MEDICAMENTS IN PARTICULAR AS ANTI-BACTERIALS |
| FR2835186B1 (en) * | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS |
| US7297714B2 (en) * | 2003-10-21 | 2007-11-20 | Irm Llc | Inhibitors of cathepsin S |
-
2007
- 2007-10-17 CA CA002667816A patent/CA2667816A1/en not_active Abandoned
- 2007-10-17 AU AU2007309195A patent/AU2007309195A1/en not_active Abandoned
- 2007-10-17 BR BRPI0717348-2A2A patent/BRPI0717348A2/en not_active Application Discontinuation
- 2007-10-17 WO PCT/US2007/081635 patent/WO2008051763A1/en active Application Filing
- 2007-10-17 EP EP07844341A patent/EP2078027A1/en not_active Withdrawn
- 2007-10-17 CN CNA2007800394622A patent/CN101589047A/en active Pending
- 2007-10-17 KR KR1020097008318A patent/KR20090064463A/en not_active Application Discontinuation
- 2007-10-17 JP JP2009534774A patent/JP2010507681A/en active Pending
- 2007-10-17 MX MX2009004290A patent/MX2009004290A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010507681A (en) | 2010-03-11 |
| AU2007309195A1 (en) | 2008-05-02 |
| BRPI0717348A2 (en) | 2013-10-15 |
| EP2078027A1 (en) | 2009-07-15 |
| WO2008051763A1 (en) | 2008-05-02 |
| KR20090064463A (en) | 2009-06-18 |
| CA2667816A1 (en) | 2008-05-02 |
| CN101589047A (en) | 2009-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009004290A (en) | Cathepsin proteases inhibitors. | |
| NO2023022I1 (en) | cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate | |
| NO20090628L (en) | Pyridizinone derivatives | |
| EA200500203A1 (en) | NEW METHOD OF SYNTHESIS AND NEW CRYSTAL FORM OF AGOMELATIN AND PHARMACEUTICAL COMPOSITIONS THAT HERE CONTAINS | |
| EA200900959A1 (en) | MEK INHIBITORS | |
| WO2007026920A3 (en) | Amide derivatives as rock inhibitors | |
| NO20073791L (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| JO2962B1 (en) | Substituted aminopropionic derivatives as neprilysin inhibitors | |
| WO2007148185A3 (en) | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors | |
| NO20071050L (en) | Rapamycin polymorph II and uses thereof | |
| NO20076554L (en) | Pyrimidine or triazine condensed bicyclic metalloprotease inhibitors | |
| IL185275A0 (en) | N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same | |
| ECSP099335A (en) | HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND METHODS OF USE OF THE SAME | |
| EA200900613A1 (en) | SPIROKETONE ACETYL-COA-CARBOXYLAS INHIBITORS | |
| WO2007125310A3 (en) | Pharmaceutical combinations of pk inhibitors and other active agents | |
| BRPI0713446A2 (en) | prolyl hydroxylase inhibitors | |
| NO20092692L (en) | MAPK / ERK kinase inhibitors | |
| EA200900135A1 (en) | DERIVATIVES OF PYRAZOL AS A CYTOCHROME P450 INHIBITORS | |
| EA200801199A1 (en) | KINASE INHIBITORS | |
| EA200800542A1 (en) | PYRIDINAMINOSULPHONE-SUBSTITUTED BENZAMIDES AS CYTOCHROME P450 3A4 INHIBITORS (CYP3A4) INHIBITORS | |
| ATE553106T1 (en) | HETEROARYLPYRROLOPYRIDINONES AS KINASE INHIBITORS | |
| NO20064344L (en) | Caspase Inhibitors and Uses thereof | |
| DE602005024274D1 (en) | AS AURORA KINASE INHIBITORS USEFUL THIENOPYRIMIDINE | |
| NO20085107L (en) | Spirocyclic nitriles as protease inhibitors | |
| WO2009010789A3 (en) | Pyrimidine derivatives 934 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FA | Abandonment or withdrawal |